Fennec Pharmaceuticals Inc., a development stage company, operates as a biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. The company’s wholly-owned subsidiary includes Adherex, Inc. Product Candidates Sodium Thiosulfate (STS) is a water soluble thiol compound that acts as a chemical reducing agent that is in two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. Eniluracil (EU) is an oral irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor, the enzyme responsible for rapidly breaking down 5-FU that is completed a Phase II clinical trial in metastatic breast cancer. STS: The company has licensed from Oregon Health & Science University (OHSU) intellectual property rights for the use of STS as a chemoprotectant, and is in the process of developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. The company has received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients. In 2007, the company announced that its collaborative partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial to investigate whether STS reduces hearing loss in children receiving cisplatin, a platinum-based chemotherapy often used in pediatric oncology. In 2008, the company announced the activation of a Phase III trial with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s Oncology Group. Eniluracil: In 2012, the company completed the enrollment of Protocol AHX-03-202, an open-label, randomized Phase II study comparing the completely oral combination of Eniluracil/5-FU/leucovorin to capecitabine monotherapy in metastatic breast cancer. Intellectual Property The company owns 23 issued patents worldwide and has 14 patents pending worldwide. With regard to STS, the company has licensed from Oregon Health and Science University one U.S. and nine foreign patents, with an additional one patent pending. With regard to Eniluracil, the company has been issued 13 patents and is prosecuting 13 additional patents. Research and Development The company’s research and development expenses totaled $0.6 million, as of December 31, 2013. History Fennec Pharmaceuticals Inc. was founded in 1996. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. It was incorporated under the Canada Business Corporations Act in 1996.
fennec pharmaceuticals inc
(FRX:Toronto Stock Exchange)
68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
|No competitor information is available for FRX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact FENNEC PHARMACEUTICALS INC, please visit www.fennecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.